Top Page
Yues International Holdings Group Limited
(1529)
Yues International Holdings Group Limited (1529) vs. iShares MSCI Hong Kong ETF (EWH)
Yues International Holdings Group Limited Business Overview & Revenue Model
Yues International Holdings Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 347.17M | 256.21M | 133.88M | 179.48M | 211.78M | 185.20M |
| Gross Profit | 38.37M | 26.52M | -21.96M | 17.70M | 19.03M | 44.87M |
| EBITDA | -11.03M | -24.09M | -26.83M | 4.23M | -7.55M | 30.92M |
| Net Income | -16.43M | -24.71M | -34.43M | -170.00K | -17.10M | 2.46M |
Balance Sheet | ||||||
| Total Assets | 276.07M | 256.83M | 282.83M | 179.21M | 184.55M | 228.03M |
| Cash, Cash Equivalents and Short-Term Investments | 134.76M | 59.72M | 78.03M | 55.53M | 108.16M | 74.97M |
| Total Debt | 6.98M | 66.07M | 78.09M | 7.59M | 9.62M | 61.64M |
| Total Liabilities | 86.05M | 123.41M | 139.02M | 35.20M | 53.92M | 93.79M |
| Stockholders Equity | 187.99M | 129.94M | 138.46M | 144.01M | 130.63M | 134.24M |
Cash Flow | ||||||
| Free Cash Flow | 13.26M | -43.13M | -34.36M | 438.00K | 6.16M | 12.92M |
| Operating Cash Flow | 14.54M | -31.50M | -33.82M | 3.39M | 6.46M | 16.70M |
| Investing Cash Flow | -24.82M | 1.30M | 27.81M | -24.33M | -5.54M | -2.67M |
| Financing Cash Flow | 50.85M | 816.00K | 29.04M | 8.56M | -7.49M | -9.43M |
Yues International Holdings Group Limited Technical Analysis
Yues International Holdings Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
53 Neutral | HK$97.00M | 9.62 | -9.70% | 20.62% | -14.78% | -212.50% | |
50 Neutral | HK$312.32M | 6.69 | -2.51% | ― | -1.40% | -128.66% | |
48 Neutral | HK$41.70M | ― | -25.91% | ― | 3.45% | -339.07% | |
47 Neutral | HK$528.38M | ― | -7.88% | ― | 9.79% | 89.05% | |
46 Neutral | HK$306.86M | ― | -9.91% | ― | 106.55% | 63.20% | |
41 Neutral | HK$451.43M | ― | -4.97% | 2.13% | -35.13% | -11.52% |
Yues International Holdings Group Limited Corporate Events
Yues International Holdings Group Limited has announced supplemental information regarding its 2024 Annual Report, focusing on its share option schemes. The New Share Option Scheme includes directors, employees, and service providers as eligible participants, aiming to support the company’s long-term growth. Additionally, the company is reallocating approximately HK$20 million of unutilized net proceeds to enhance its Chinese medicine business, with plans to fully utilize these funds by the end of 2026. This strategic move is expected to bolster the company’s operations and market positioning.
Yues International Holdings Group Limited has announced a change in the use of proceeds from a recent share placement. Originally intended for the development of its Intelligent Logistics Services Business, the company has decided to reallocate the remaining HK$30 million to its Chinese Medicine Business and general working capital. This strategic shift aligns with the company’s recent expansion into pharmaceutical distribution, aiming to capitalize on market opportunities and enhance shareholder value without adversely affecting its existing operations.
Yues International Holdings Group Limited, a company listed on the Hong Kong Stock Exchange, announced a change in its auditing firm due to an inability to agree on audit fees with its previous auditor, Baker Tilly Hong Kong Limited. The company has appointed Moore CPA Limited as the new auditor, citing Moore’s experience, independence, and capability to maintain audit quality as reasons for the change. The board believes this transition will not impact the company’s annual audit or results.
Yues International Holdings Group Limited has announced the acquisition of Bozhou Lelaohao Medical Co., Ltd., a company engaged in the wholesale and distribution of pharmaceutical products. This acquisition aligns with Yues International’s strategic objectives to enhance its logistics capabilities in the Chinese medicine sector and expand its supply chain services. The company plans to integrate digital technologies and AI to improve operational efficiency and explore further opportunities along the industry chain, while also addressing potential risks in compliance, supply chain management, and quality control to enhance market competitiveness.
Yues International Holdings Group Limited has announced the composition of its Board of Directors, which comprises seven members, including both executive and independent non-executive directors. The company operates with a structured governance framework, having established three Board committees: Audit, Remuneration, and Nomination, each with defined terms of reference. This announcement reflects the company’s commitment to maintaining a robust governance structure, which is crucial for its operational integrity and strategic direction. The appointment of directors to specific roles within these committees indicates a clear delineation of responsibilities, which is likely to enhance decision-making processes and stakeholder confidence.
Yues International Holdings Group Limited has established a nomination committee to enhance its corporate governance practices. The committee, composed primarily of independent non-executive directors, is tasked with reviewing the board’s structure, identifying qualified board candidates, assessing director independence, and ensuring diversity. This initiative is expected to strengthen the company’s strategic alignment and governance, potentially impacting its market positioning positively.
Yues International Holdings Group Limited announced that all resolutions proposed at their Annual General Meeting (AGM) held on June 18, 2025, were passed unanimously by shareholders. The resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to issue and repurchase shares. This unanimous approval reflects strong shareholder support and positions the company for continued operational stability and strategic flexibility.
Yues International Holdings Group Limited has announced the composition of its board of directors, which includes a mix of executive and independent non-executive directors. The board comprises seven directors, with Mr. Le Kang serving as Chairman and Mr. Li Zhigang as the Chief Executive Officer. The company has established three board committees: Audit, Remuneration, and Nomination, with defined roles for each director within these committees. This announcement reflects the company’s commitment to structured governance and oversight, potentially enhancing its strategic decision-making and operational efficiency.
Yues International Holdings Group Limited has announced the resignation of Mr. Chan Koon Yung as an independent non-executive director, effective May 22, 2025, due to personal and work commitments. Consequently, Mr. Zhang Yao has been appointed to the audit, remuneration, and nomination committees, replacing Mr. Chan. Additionally, the ordinary resolution for Mr. Chan’s re-election at the upcoming annual general meeting has been withdrawn.